相关实验视频
Updated: Sep 14, 2025
07:48
An Orthotopic Bladder Cancer Model for Gene Delivery Studies
Published on: December 1, 2013
12.6K
准BACH1/PSPH轴通过降低S100A2表达的调节来抑制膀癌的进展和凝胺耐药性
Tingxuan Ma1, Jing Ma2, Yipin Wang2
1The First Affiliated Hospital, Dalian Medical University, Dalian 116044, PR China.
Biochemical pharmacology
|July 20, 2025
概括
素酸酶 (PSPH) 通过增加S100A2.2,驱动膀癌 (BCa) 的进展和凝素耐药性. 布鲁萨托尔通过降解PSPH调节器BACH1来抑制这种途径,为BCa.提供了潜在的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 素酸酶 (PSPH) 与瘤发生有关.
- 在膀癌 (BCa) 中PSPH的作用和调节尚未得到充分理解.
研究的目的:
- 研究PSPH在膀癌 (BCa) 中的作用和调节机制.
- 探索布鲁萨托尔作为治疗剂的潜力,以向BCa.a.中的BACH1/PSPH/S100A2通路.
主要方法:
- 在BCa组织中分析PSPH表达和与患者存活率的相关性.
- 试验室实验涉及PSPH枯竭和BCa细胞的上调.
- 调查PSPH,S100A2,BACH1和Brusatol之间的监管关系.
主要成果:
- 在BCa组织中,PSPH表达显著上调,与较差的生存率相关.
- PSPH 枯竭抑制BCa细胞生长和转移;其上调促进进展和耐 gemcitabine (GEM).
- PSPH增强了S100A2的表达,导致恶性病变的进展. 巴赫1促进PSPH的表达,而布鲁萨托尔降解了巴赫1,降低了该途径的调节.
结论:
- PSPH在BCa中起着关键的致癌作用,通过S100A2.2.促进进展和GEM耐药性.
- BACH1/PSPH/S100A2通路是BCa恶性瘤的关键调节者.
- 布鲁萨托尔通过向BACH1来抑制BCa进展和GEM耐药性,这是一种新的治疗方法.
更多相关视频
09:243-D Cell Culture System for Studying Invasion and Evaluating Therapeutics in Bladder Cancer
Published on: September 13, 2018
9.1K
11:02Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
21.4K
相关概念视频
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
02:50Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K